Improvements in Patient-Reported Outcome Measures Through 64 Weeks' Rimegepant Treatment for Migraine: Analysis of a Randomized Controlled Trial with Open-Label Extension.

In a recent study, researchers examined how rimegepant improves migraine treatment over 64 weeks. This involved 741 participants, mostly women, aged about 41 years. The study had two phases: a 12-week double-blind treatment phase and a 52-week open-label extension. Participants were given either rimegepant or a placebo during the first phase. After the initial phase, all participants received rimegepant. Researchers measured outcomes using two questionnaires: the Migraine-Specific Quality of Life Questionnaire and the Migraine Disability Assessment Scale. Results showed that those taking rimegepant experienced significant improvements in their quality of life and reduced migraine-related disability. These findings suggest that rimegepant may be an effective preventive treatment for migraines, helping patients manage their symptoms better and improve their daily lives over time. Overall, the study highlights the potential of rimegepant as a valuable option for migraine sufferers. Clinical relevance: This study indicates that rimegepant may significantly enhance quality of life for migraine patients, suggesting it could be a beneficial preventive treatment option for clinicians to consider.